ment in schizophrenia: an open-label study. J Neural Transm 95:
105–111.
Chambers RA, Krystal JH, Self DW (2001). A neurobiological basis
for substance abuse comorbidity in schizophrenia. Biol Psychiatry 50: 71–83.
Craven SE, Bredt DS (1998). PDZ proteins organize synaptic
signaling pathways. Cell 93: 495–498.
Detera-Wadleigh SD, Badner JA, Berrettini WH, Yoshikawa T,
Goldin LR, Turner G et al (1999). A high-density genome scan
detects evidence for a bipolar susceptibility locus on 13q32 and
other potential loci on 1q32 and 18p11.2. Proc Natl Acad Sci USA
96: 5604–5609.
Dracheva S, Marras SAE, Elhakem SL, Kramer FR, Davis KL,
Haroutunian V (2001). N-methyl-D-aspartic acid receptor
expression in the dorsolateral prefrontal cortex of elderly
patients with schizophrenia. Am J Psychiatry 158: 1400–1410.
Gao X-M, Shirakawa O, Du F, Tamminga CA (1993). Delayed
phencyclidine-induced alterations in local cerebral glucose
utilization. Eur J Pharmacol 241: 7–15.
Gao X-M, Tamminga CA (1994). An increase NMDA-sensitive
[3H]glutamate and [3H]kainate binding in hippocampus 24
hours after PCP. Neurosci Lett 174: 149–153.
Gao X-M, Tamminga CA (1996). Phencyclidine produces changes
in NMDA and kainate receptor binding in rat hippocampus over
a 48-hour time course. Synapse 23: 274–279.
Goff DC, Coyle JT (2001). The emerging role of glutamate in the
pathophysiology and treatment of schizophrenia. Am J Psychiatry 158: 1367–1377.
Goff DC, Tsai G, Manoach DS, Coyle JT (1995). Dose-finding trial
of D-cycloserine added to neuroleptics for negative symptoms in
schizophrenia. Am J Psychiatry 152: 1213–1215.
Greifenstein FE, Yoshitake J, DeVault M, Gajewski JE (1958). A
study of 1-aryl-cyclohexylamine for anesthesia. Anesth Analg 37:
283–294.
Heid CA, Stevens J, Livak LJ, Williams PM (1996). Real time
quantitative PCR. Genome Res 6: 986–994.
Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Kelly D (1996).
Double-blind, placebo-controlled crossover trial of glycine
adjuvant therapy for treatment-resistant schizophrenia. Br J
Psychiatry 169: 610–617.
Javitt DC, Zukin SR (1991). Recent advances in the phencyclidine
model of schizophrenia. Am J Psychiatry 148: 1301–1308.
Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer J- P (1994). Amelioration of negative symptoms in schizophrenia
by glycine. Am J Psychiatry 151: 1234–1236.
Kennedy MB (1998). Signal transduction molecules at the
glutamatergic postsynaptic membrane. Brain Res Rev 26: 243–
257.
Kim E, Naisbitt S, Hsueh Y-P, Rao A, Rothschild A, Craig AM et al
(1997). GKAP, a novel synaptic protein that interacts with the
guanylate kinase-like domain of the PSD-95/SAP90 family of
channel clustering molecules. J Cell Biol 136: 669–678.
Kornau H-C, Schenker LT, Kennedy MB, Seeburg PH (1995).
Domain interaction between NMDA receptor subunits and
the postsynaptic density protein PSD-95. Science 269:
1737–1740.
Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner
JD et al (1994). Subanesthetic effects of the noncompetitive
NMDA antagonist ketamine in humans: psychotomimetic
perceptual cognitive and neuroendocrine responses. Arch Gen
Psychiatry 51: 199–214.
Laemmli UK (1970). Cleavage of structural proteins during the
assembly of the head of bacteriophage T4. Nature 227: 680–685.
Lahti AC, Holcomb HH, Medoff DR, Tamminga CA (2001).
Ketamine activates psychosis and alters limbic blood flow in
schizophrenia. Neuroreport 6: 869–872.
Lau L-F, Mammen A, Ehlers ME, Kindler S, Chung WJ, Garner CC
et al (1996). Interaction of the N-methyl-D-aspartate receptor
